外周血造血干细胞动员采集264例临床分析

目的 探讨外周血造血干细胞动员采集的方法及其效果.方法 对恶性血液病患者及健康供者经单一生长因子和化疗联合生长因子方案动员后,使用CS3000 Plus3000血细胞分离机(Baxter公司)进行外周血造血干细胞采集,对不同动员方案、疾病、年龄、性别及供者的动员采集效果进行分析.结果 所有患者均成功动员采集.健康供者较恶性血液病患者动员效果佳;在恶性血液病中,非霍奇金淋巴瘤动员效果最好,多发性骨髓瘤最差.恶性血液病患者中,采集所获得的单个核细胞数中,非霍奇金淋巴瘤最好,多发性骨髓瘤最差,在采集所获得的CD34 细胞数中,急性淋巴细胞白血病最好,多发性骨髓瘤最差;化疗联合G-CSF和IL-11为最好的动员方案;成人采集效果最好,老年患者最差;男性较女性好.健康供者男女采集效果无差别;健康供者较恶性血液病患者采集效果好.无论是健康供者还是恶性血液病患者,动员采集过程中不良反应较小.结论 根据不同的疾病、性别、年龄,采用不同的动员采集方案,一般可以成功采集.

Clinical analysis on mobilization and collection of peripheral hematopoietic stem cells

Objective To investigate the method and efficiency of mobilization and collection of peripheral hematopoietic stem cells.Methods After mobilization with single cytokine and combination of chemotheraphy with cytokine of the patients of malig-nant hemopathy and the heathy donors,the peripheral blood hematopoietic stem cells were collected by CS3000 PLUS blood cell separator(Baxter corporation).The result of mobilizatin and collection for different diseases,ways of mobilization,age,sex and donor was analyzed.Results All cases were successful in mobilization and collection.The result of mobilization of the heathy do-nors was better than that of the patients of malignant hemopathy.In the patients of malignant hemopathy,the result of mobiliza-tion for non-Hodgkin lymphoma was the best and multiple myeloma was the worst,acute nonlymphoblastic leukemia was the best and multiple myeloma was the worst for the number of monocular nuclear cell of collection and acute lymphoblastic leukemia was the best and multiple myeloma was the worst for CD34+,the best protocol of mobilization was combination of chemotheraphy with G-SCF and IL-11,the best efficiency of collection was adults and older patients was the worst,and man was better than women.There was no difference in collection between sex in the healthy donors.The result of collection in the healthy donors was better than that in the patients of malignant hemopathy.Adverse effect was little in the course.Conclusion It can successfully collect pe-ripheral hematopoietic stem cells with different protocol according to different dieases,sex and age.